Abstracts tagged "Enthesitis and psoriatic arthritis"

Abstract Number: 630 • 2019 ACR/ARP Annual Meeting
Assessing the Humanistic and Economic Burden of Enthesitis Among Patients with Peripheral and Axial Spondyloarthritis: Results from a Multi-National Real World Survey Database
Vibeke Strand ¹, Atul Deodhar ², Philip G Conaghan ³, Isabelle Gilloteau ⁴, Olivia Massey ⁵, Haijun Tian ⁶, Aurore Yocolly ⁷, Nicola Booth⁵ and Rieke Alten ⁸, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²Oregon Health & Science University, Portland, OR, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Adelphi Real World, Bollington, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Product Lifecycle Services –NBS, Novartis Global Service Center, Dublin, Ireland, ⁸Schlosspark-Klinik University Medicine, Berlin, Germany
Background/Purpose: Enthesitis is a major source of pain, functional impairment, and reduced health-related quality of life (HRQoL) in spondyloarthritis (SpA) patients; however, limited information is…
Abstract Number: 2579 • 2018 ACR/ARHP Annual Meeting
Ixekizumab Treatment Significantly Improves Enthesitis and Dactylitis in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials
Dafna D Gladman¹, Ana-Maria Orbai², Gaia Gallo³, Julie Birt³, Suchitrita Rathmann³ and Helena Marzo-Ortega⁴, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Eli Lilly and Company, Indianapolis, IN, ⁴NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom
Background/Purpose: Ixekizumab (IXE), an IL-17A antagonist, is approved in the USA for the treatment of PsA including patients (pts) with pre-existing enthesitis or dactylitis. Previous…
Abstract Number: 1710 • 2015 ACR/ARHP Annual Meeting
Enthesitis in Psoriatic Arthritis: Incidence, Prevalence and Characteristics
Ari Polachek¹, Suzanne Li², Vinod Chandran¹ and Dafna Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis reflects inflammation at the insertion of tendons and ligaments into bone and is a well-known component of psoriatic arthritis (PsA). It is part…
Abstract Number: 1711 • 2015 ACR/ARHP Annual Meeting
Enthesitis in Psoriatic Arthritis – Disease Association and Risk Factors
Ari Polachek¹, Suzanne Li², Vinod Chandran¹ and Dafna Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease presenting with musculoskeletal and extra-articular manifestation. Enthesitis is a well-known component of PsA. However, little is known…
Abstract Number: 551 • 2012 ACR/ARHP Annual Meeting
Prevalence of Enthesitis in Psoriatic Patients: Agreement Between Clinical and Power Doppler Ultrasonography Exploration and Its Implications for the Classification of Psoriatic Arthritis
Jose Luis Fernandez-Sueiro¹, JA Pinto¹, S. Pertega-Diaz² and Carlos Fernandez-Lopez³, ¹Rheumatology Division, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ²Epidemiology and Statistics, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ³INIBIC- Complejo Hospitalario Universitario La Coruña(CHUAC). Rheumatology Division., La Coruña, Spain
Background/Purpose: Enthesitis constitutes one of the CASPAR stem criteria for the classification of psoriasis arthritis, however as enthesitis may be clinically silent many psoriatic patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].